Bioavailability In-Vivo Production Trials 
Camargo
FEBRUARY 10, 2021
Drug development is an extremely cumbersome process, requiring the testing of an agent from in vitro studies to in vivo studies to in silico modeling. Given that it can take up to 20 years for a final product to be approved, it is unsurprising that drug attrition rates are very high. Approaches to Pharmacokinetic Analysis.
Camargo
DECEMBER 22, 2021
One of Camargo’s differentiating offerings is the portfolio analysis, a high-level, integrated evaluation of the scientific, medical, regulatory, and commercial viability of each product within a sponsor’s portfolio. Each product is unique, and so is the associated development strategy. Why Conduct a Portfolio Analysis?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Camargo
SEPTEMBER 30, 2021
Nonclinical programs include (but are not limited to) method development and validation, pharmacokinetic studies, in vivo efficacy studies, safety pharmacology, IND-enabling toxicology studies, and long-term studies when appropriate. Overview of Drug Development Programs (Through IND Submission). CMC Considerations. Non-scalable process.
Pharmaceutical Technology
FEBRUARY 13, 2023
Best practice is to also consider the ‘developability’ of the lead compounds in conjunction with any evidence of potential in-vivo activity, by taking a holistic approach. With all this in mind, how do drug developers know which strategy and approach is right for their molecule at this early stage?
Pharmaceutical Technology
FEBRUARY 23, 2023
Quotient Sciences helps biotech and pharma customers in the development and optimization of drug products. How does bioavailability play a role in biopharmaceutics? Now fraction absorbed and bioavailability are often confused and used interchangeably.
Expert insights. Personalized for you.
133 
Let's personalize your content